Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04553666 · ClinicalTrials.gov registry record · Phase 2
Reducing Frailty for Older Cancer Survivors Using Supplements
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT04553666 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 24 participants.
The verdict
NCT04553666, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of the study is to examine the feasibility and safety of twelve weeks oral supplementation of Epigallocatechin-3-gallate (EGCG) in older survivors of cancer
Interventions
- DRUG Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04553666
The ClinicalTrials.gov registry entry for NCT04553666 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C) is the first listed.
NCT04553666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04553666 about?
NCT04553666 is a clinical study titled "Reducing Frailty for Older Cancer Survivors Using Supplements". The purpose of the study is to examine the feasibility and safety of twelve weeks oral supplementation of Epigallocatechin-3-gallate (EGCG) in older survivors of cancer
What is the current status of trial NCT04553666?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2021-04-28. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT04553666?
The interventions under investigation include: Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C) (DRUG).
Who is sponsoring clinical trial NCT04553666?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.